Taro Pharmaceutical Industries Ltd (TARO)
42.20
-0.03
(-0.07%)
USD |
NYSE |
Apr 24, 16:00
42.21
+0.01
(+0.02%)
Pre-Market: 20:00
Taro Pharmaceutical Industries Revenue (Quarterly): 157.14M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 157.14M |
| September 30, 2023 | 148.20M |
| June 30, 2023 | 158.89M |
| March 31, 2023 | 146.59M |
| December 31, 2022 | 139.20M |
| September 30, 2022 | 130.50M |
| June 30, 2022 | 156.66M |
| March 31, 2022 | 143.26M |
| December 31, 2021 | 138.98M |
| September 30, 2021 | 131.99M |
| June 30, 2021 | 147.11M |
| March 31, 2021 | 148.35M |
| December 31, 2020 | 140.14M |
| September 30, 2020 | 142.84M |
| June 30, 2020 | 117.63M |
| March 31, 2020 | 174.94M |
| December 31, 2019 | 147.68M |
| September 30, 2019 | 160.85M |
| June 30, 2019 | 161.30M |
| March 31, 2019 | 179.92M |
| December 31, 2018 | 176.38M |
| September 30, 2018 | 158.97M |
| June 30, 2018 | 154.62M |
| March 31, 2018 | 175.22M |
| December 31, 2017 | 155.46M |
| Date | Value |
|---|---|
| September 30, 2017 | 169.92M |
| June 30, 2017 | 161.32M |
| March 31, 2017 | 196.41M |
| December 31, 2016 | 220.40M |
| September 30, 2016 | 228.79M |
| June 30, 2016 | 233.78M |
| March 31, 2016 | 265.07M |
| December 31, 2015 | 258.34M |
| September 30, 2015 | 212.06M |
| June 30, 2015 | 215.28M |
| March 31, 2015 | 244.18M |
| December 31, 2014 | 237.70M |
| September 30, 2014 | 250.83M |
| June 30, 2014 | 130.23M |
| March 31, 2014 | 187.18M |
| December 31, 2013 | 213.60M |
| September 30, 2013 | 205.32M |
| June 30, 2013 | 153.20M |
| March 31, 2013 | 165.13M |
| December 31, 2012 | 185.70M |
| September 30, 2012 | 160.97M |
| June 30, 2012 | 159.15M |
| March 31, 2012 | 145.14M |
| December 31, 2011 | 148.10M |
| September 30, 2011 | 138.25M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
117.63M
Minimum
Jun 2020
174.94M
Maximum
Mar 2020
146.96M
Average
147.11M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| InspireMD Inc | 1.761M |
| Ayala Pharmaceuticals Inc | -- |
| BiomX Inc | -- |
| Alpha Tau Medical Ltd | -- |
| Pluri Inc | 0.105M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 20.21M |
| Total Expenses (Quarterly) | 141.26M |
| EPS Diluted (Quarterly) | 0.54 |
| Enterprise Value | 683.85M |
| Gross Profit Margin (Quarterly) | 50.83% |
| Profit Margin (Quarterly) | 12.86% |
| Earnings Yield | 2.89% |
| Operating Earnings Yield | 1.39% |
| Normalized Earnings Yield | 2.886 |